anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A fluid composition for coating tablets consists essentially of 10-25 grms. by weight of a water-soluble wax as hereinafter defined, 5-12 grms. by weight of a polymeric substance comprising a polyalkylmethacrylate, a copolymer of an alkyl acrylate with an alkylmethacrylate or a copolymer of an alkylmethacrylate with methacrylic acid, the alkyl having 1 to 4 carbon atoms, together with a non-aqueous solvent to a volume of 100 ml. of the ultimate composition.  The wax is a water-soluble polyethylene glycol of melting point of at least 50 DEG C., glyceryl monostearate, diglycol stearate, and mixtures thereof.  Optional ingredients are (a) dyes, lakes and pigments (b) water-insoluble glossing and polishing agents, e.g. beeswax, lanolin, stearic acid, cocoa butter and cetyl alcohol (c) plasticizers such as castor oil, mineral oil, corn oil, sesane oil and propylene glycol, alone or in admixture with a drying oil such as soya bean oil (d) surface-active agents, e.g. polyoxyethylene sorbitan derivatives and sulphated fatty alcohols (e) vinyl stearate (antisticking agent).  Specifications 762,229 and 764,342 are referred to.ALSO:A coated solid medicament has the coating material in the form of a physiologically acceptable composition consisting essentially of a water-permeable combination of a water-soluble or water dispersible wax (A) and a film-forming "plastic" which is a polymer of an alkylmethacrylate a copolymer of an alkyl acrylate with an alkyl methacrylate or a copolymer of an alkylmethacrylate with methacrylic acid, the said alkyl having 1 to 4 carbon atoms (B).  The copolymers contain 70 to 95% of the acrylate or methacrylate.  The waxes are polyethylene glycols of melting point at least 50 DEG  C., glyceryl monostearate and diglycol stearate, or mixtures thereof. Optional ingredients are (a) dyes, lakes and pigments; (b) water-insoluble glossing and polishing agents such as beeswax, lanolin, stearic acid, cocoa butter and cetyl alcohol (C); (c) plasticizers such as castor oil, mineral oil, corn oil, sesame oil and propylene glycol, alone or in admixture with a drying oil such as soy bean oil (D); (d) surface-active agents such as polyoxyethylene sorbitan derivatives and sulphated fatty alcohols; and (e) an anti-sticking agent which is vinyl stearate. The compositions contain 10 to 25 grms. of (A), 5 to 12 grms. of (B), not more than 1 grm. of (C) and not more than 2 grms. of (D) per 100 ml. of the fluid composition which is prepared by dissolving the components in a non-aqueous solvent such as acetone, ethanol, or mixtures thereof, methyl ethyl ketone or ethyl acetate.  The finished coat contains 45 to 83% of (A) and 17 to 55% of (B) and not more than 5% of the optional components. Specifications 762,229 and 764,342 are referred to.
Atropine-induced parasympathetic inhibition may be preceded by a transient phase of stimulation, especially on the heart where small doses first slow the rate before characteristic tachycardia develops due to paralysis of vagal control. Atropine exerts a more potent and prolonged effect on heart, intestine and bronchial muscle than scopolamine, but its action on the iris, ciliary body and certain secretory glands is weaker than that of scopolamine. Unlike the latter, atropine in clinical doses does not depress the central nervous system but may stimulate the medulla and higher cerebral centers. Although mild vagal excitation occurs, the increased respiratory rate and (sometimes) increased depth of respiration produced by atropine are more probably the result of bronchiolar dilatation. Accordingly, atropine is an unreliable respiratory stimulant and large or repeated doses may depress respiration.

Adequate doses of atropine abolish various types of reflex vagal cardiac slowing or asystole. The drug also prevents or abolishes bradycardia or asystole produced by injection of choline esters, anticholinesterase agents or other parasympathomimetic drugs, and cardiac arrest produced by stimulation of the vagus. Atropine also may lessen the degree of partial heart block when vagal activity is an etiologic factor. In some patients with complete heart block, the idioventricular rate may be accelerated by atropine; in others, the rate is stabilized. Occasionally a large dose may cause atrioventricular (A-V) block and nodal rhythm.

Atropine Sulfate Injection in clinical doses counteracts the peripheral dilatation and abrupt decrease in blood pressure produced by choline esters. However, when given by itself, atropine does not exert a striking or uniform effect on blood vessels or blood pressure. Systemic doses slightly raise systolic and lower diastolic pressures and can produce significant postural hypotension. Such doses also slightly increase cardiac output and decrease central venous pressure. Occasionally, therapeutic doses dilate cutaneous blood vessels, particularly in the "blush" area (atropine flush) and may cause atropine "fever" due to suppression of sweat gland activity in infants and small children.

The effects of intravenous atropine on heart rate (maximum heart rate) and saliva flow (minimum flow) after intravenous administration (rapid, constant infusion over 3 min.) are delayed by 7 to 8 minutes after drug administration and both effects are non-linearly related to the amount of drug in the peripheral compartment. Changes in plasma atropine levels following intramuscular administration (0.5 to 4 mg doses) and heart rate are closely overlapped but the time course of the changes in atropine levels and behavioral impairment indicates that pharmacokinetics is not the primary rate-limiting mechanism for the central nervous system effect of atropine.
The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells. Also provided are medical uses of the inventive antibodies or conjugates and/or treatment methods comprising the administration of these antibodies to a patient or subject, either alone or in combination. Biomarkers, stratification methods and diagnostic methods are finally provided to predict or evaluate responsiveness to anti-CCR8 antibody monotherapy or combination therapy. The invention furthermore provides tools and methods for producing the foregoing antibodies, pharmaceutical compositions, diagnostic uses of the antibodies, and kits with instructions for use.
This project proposes using a two-armed, waitlist controlled trial to test the effectiveness of peer-facilitated travel interventions and their ability to enhance community mobility and increase feelings of self-efficacy in individuals with serious mental illness (SMI). The first intervention arm is an 8-week bikeshare intervention, which consists of individual trainings on using a bike sharing program; the second intervention arm is an 8-week public transportation intervention, which consists of individual trainings for using public transportation in the Philadelphia area. The investigators seek to enroll a total of 180 individuals from community mental health agencies in the Philadelphia area and expect recruitment to take 3 years. Eligible participants will be individuals who meet criteria indicating that they have an SMI, are between the ages of 18-65, and are both willing and able to learn to use public transportation and ride a bicycle. Data will be collected via face-to-face or web-based video call interviews at 3 time points: baseline, 2-months post-baseline, and 4-months post-baseline. Participants will also complete short surveys about their travel behaviors over the phone in the seven days after each interview. There will also be a subsample of participants who will provide additional GPS data.
Patients will receive induction therapy (sintilimab + bevacizumab + gemcitabine, Q3W, 3 cycles) followed by IMRT+ Sintilimab. Consolidation therapy with sintilimab continued after radiotherapy until disease progression, intolerable toxicity, death, or the subject's decision to withdraw from the study, with a total treatment period of no more than 12 cycles.
PURPOSE: A PENTEC (Pediatric Normal Tissue Effects in the Clinic) review was performed to estimate the dose-volume effects of radiation therapy on spine deformities and growth impairment for patients who underwent radiation therapy as children.
METHODS AND MATERIALS: A systematic literature search was performed to identify published data for spine deformities and growth stunting. Data were extracted from 12 reports of children irradiated to the spine (N = 603 patients). The extracted data were analyzed to find associations between complication risks and the radiation dose (conventional fractionation throughout) as impacted by exposed volumes and age using the mixed-effects logistic regression model. When appropriate, corrections were made for radiation modality, namely orthovoltage beams.
RESULTS: In the regression analysis, the association between vertebral dose and scoliosis rate was highly significant (P < .001). Additionally, young age at time of radiation was highly predictive of adverse outcomes. Clinically significant scoliosis can occur with doses ≥15 Gy to vertebrae during infancy (<2 years of age). For children irradiated at 2 to 6 years of age, overall scoliosis rates of any grade were >30% with doses >20 Gy; grade 2 or higher scoliosis was correlated with doses ≥30 Gy. Children >6 years of age remain at risk for scoliosis with doses >30 Gy; however, most cases will be mild. There are limited data regarding the effect of dose gradients across the spine on degree of scoliosis. The risk of clinically meaningful height loss was minimal when irradiating small volumes of the spine up to 20 Gy (eg, flank irradiation), except in infants who are more vulnerable to lower doses. Growth stunting was more frequent when larger segments of the spine (eg, the entire spine or craniospinal irradiation) were irradiated before puberty to doses >20 Gy. The effect was modest when patients were irradiated after puberty to doses >20 Gy.
CONCLUSIONS: To reduce the risk of kyphoscoliosis and growth impairment, the dose to the spine should be kept to <20 Gy for children <6 years of age and to <10 to 15 Gy in infants. The number of vertebral bodies irradiated and dose gradients across the spine should also be limited when possible.
PROBLEM TO BE SOLVED: To obtain chitosan nanospheres which are not caught by a xenobiotic exclusion mechanism and are used for the delivery and slow release of a drug by bonding a compd. having a polyalkylene glycol part to chitosan through the surface amino groups. SOLUTION: An aq. soln. of chitosan (β-1,4-poly-D-glucosamine) is emulsified with an org. solvent in the presence of a surfactant of a quaternary ammonium salt type and reacted with a polyalkylene-glycolating reagent to produce chitosan nanospheres with a compd. having a polyalkylene glycol part bonded to their surfaces through amino groups and having an average particle size of 1,000nm or lower. The produced nanospheres has a biocompatibility, can avoid a reticuloendothelial system because of its hydrophilic surface, and can be expected as a medicine for a drug delivery system.
The methods and techniques will be the same as those used in the group intervention. The first session will be used for a detailed assessment of the individual's psychosocial problems, as used in earlier studies. The sessions will last 45 - 60 minutes. The number of sessions will depend on the individual patient's problems and the joint assessment made by the patient and nurse together. The total number of sessions will be at least 4, with a maximum of 8. The contents of the sessions are Session 1: Assessment, Session 2: Analysis of diary (self-registration) and suggestions for problem management, Session 3: Evaluation of problem management skills Session 4: Follow-up and conclusion of the intervention. When necessary Sessions 5 -8 will address specific obstacles and continued practice.
BACKGROUND: Schistosoma japonicum (S. japonicum) is the main species of Schistosoma prevalent in China. Myeloid-derived suppressor cells (MDSCs) are important immunoregulatory cells and generally expand in parasite infection, but there is little research relating to MDSCs in Schistosoma infection.
METHODS: Fifty-six S. japonicum-infected patients were included in this study. MDSCs and percentages and absolute cell numbers of lymphocyte subsets, including CD3+ T cells, CD4+ T cells, CD8+ T cells, B cells and natural killer (NK) cells were detected using flow cytometry. The degree of liver fibrosis was determined using color Doppler ultrasound.
RESULTS: Patients infected with S. japonicum had a much higher percentage of MDSCs among peripheral blood mononuclear cells (PBMCs) than the healthy control. Regarding subpopulations of MDSCs, the percentage of granulocytic myeloid-derived suppressor cells (G-MDSCs) was clearly increased. Correlation analysis showed that the absolute cell counts of T-cell subsets correlated negatively with the percentages of MDSCs and G-MDSCs among PBMCs. The percentage of G-MDSCs in PBMCs was also significantly higher in patients with liver fibrosis diagnosed by color doppler ultrasound (grade > 0), and the percentage of G-MDSCs in PBMCs and liver fibrosis grading based on ultrasound showed a positive correlation.
CONCLUSION: S. japonicum infection contributes to an increase in MDSCs, especially G-MDSCs, whose proliferation may inhibit the number of CD4+ T cells in peripheral blood. Meanwhile, there is a close relationship between proliferation of G-MDSCs and liver fibrosis in S. japonicum-infected patients.
The present invention relates to a method for delivering a drug to a local body site. More specifically, the present invention relates to methods of delivering drugs, such as antibiotics, to periodontal tissues, and is in the field of pharmaceutical technology. The present invention is directed to a formulation for delivering a drug, such as an antibiotic, into diseased local tissue, such as periodontal tissue. Preferably the material is a biodegradable oligomer or polymer. The oligomer or polymer containing the drug is heated at a physiologically compatible elevated temperature and then delivered to the local tissue, preferably by injection. Once the biodegradable material is injected into the local tissue, the material cools to body temperature. As it cools, the material hardens and remains in place in the local tissue. The hardened material biodegrades in the tissue and continues to release the drug over a period of days.
The present invention relates to a prescription for treating eye diseases by external application on a navel. 36 traditional Chinese medicines including oyster shell, milkvetch root, etc. are baked and ground into medicine velour powder which is uniformly mixed to be applied on a patient's umbilical part. The prescription for treating eye diseases is created on the basis of the internal reasons of eye diseases, the reference of ancient and modern medical records and secret prescriptions, and the combination of Chinese medicine theory and clinical experience. The prescription for treating eye diseases has the main functions of nourishment and consolidation of the constitution and is matched with a medicine which can dredge channels, improve eyesight, induct resuscitation and lift up incense; after being absorbed through the umbilical part, the medicine is dispersed into a body to strengthen and coordinate the function of each organ. The present invention has the advantages of easy acquirement of raw material, easy processing and convenient treatment. The medicine can strengthen physique and improve eyesight, and especially myopia and amblyopia eyesight can be enhanced from 0.1 to over 0.8.
The present invention relates to taxus plant extract, an extraction method for the extract and an application thereof, particularly to plant extract, an extraction technology thereof and an application to anti-cancer medicine. The taxus plant extract of the present invention is extracted by using branches and leaves of northeast yew as raw materials, and comprises the components of taxane diterpene compounds, total lignanoid and total flavonoid. After branches and leaves of yew are concentrated and extracted, the taxus plant extract is obtained through pressure reduction and concentration, and the extract can be used as active components of anti-cancer medicine. The present invention is novel medicine prepared by medical sites of taxus plants, and contains various anti-cancer active components. The present invention has the characteristics of high yield, low cost, etc., and the anti-cancer effect is as good as paclitaxel. Meanwhile, the continuous utilization of taxus plants is realized, and the present invention has the advantage of low side effect. The utilization rate is improved by more than 25 times on the premise that therapeutic effect is ensured.
Subjects in IG3 will be given a animation video screening in a specific room. IG3 intervention is on two topics cover only. The animation educational video covers on the topic of effective toothbrushing technique, and dental caries.
Patients receive oral vorinostat (SAHA) twice daily and oral isotretinoin twice daily on days 3-5, 10-12, 17-19, and 24-26. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Integrated Cognitive Behavioral Therapy (ICBT) is a non-exposure based, manual-guided individual or group therapy. ICBT consists of 3 learning and skill components designed to improve PTSD symptoms and substance use: 1) Patient education about PTSD and its relation to substance use and treatment; 2) Mindful relaxation: A behavioral anxiety reduction skill including centering and breathing techniques; and 3) Cognitive restructuring/flexible thinking: A cognitive approach and functional analysis of the link among emotions, cognitives and situations.
Follow-up colonoscopy after abnormal stool-based colorectal cancer screening (e.g., fecal immunochemical test (FIT)) results in early detection of colorectal cancer (CRC), prevention of CRC, and reduction in CRC mortality. FIT is a commonly utilized screening test that can be performed at home, is inexpensive, scalable, and often adopted in health systems where colonoscopy resources are scarce. Despite evidence that timely colonoscopy is necessary after an abnormal FIT result, completion of colonoscopy occurs in less than 50% of patients at 6 months and varies significantly by clinic and health systems. In addition to understanding the meaning of an abnormal FIT, three care transitions must occur smoothly for the patient: colonoscopy referral, scheduling, and attendance. However, multilevel factors influence missed follow-up, and multilevel solutions are needed along the care continuum to address clinic-, provider-, and patient-level factors that impair or delay colonoscopy completion.

IMProving Adherence to Colonoscopy through Teams and Technology (IMPACTT), proposes to close gaps and reduce disparities in CRC screening by improving the completion of diagnostic colonoscopy following abnormal FIT in vulnerable populations using a multilevel approach consisting of interventions at the clinic-, provider- and patient-level. The specific aims are 1) to evaluate the effect of a clinic-level intervention targeting primary care providers and staff to adopt "best practices" to support colonoscopy completion in patients with abnormal FIT results, 2) to determine the effect of a patient-level technology intervention with enhanced instructions and navigation for patients with abnormal FIT to complete a diagnostic colonoscopy, and 3) to explore the multilevel implementation factors contributing to intervention outcomes using mixed methods.
<P>PROBLEM TO BE SOLVED: To provide WPC (whey protein concentrate) mixed with iron and excellent in absorption of iron and anemia ameliorating effect through effectively using whey produced as by-products of cheese and casein, and to provide a method for producing the WPC.  <P>SOLUTION: The whey protein concentrate mixed with iron contains 0.001-0.05 pt.wt. of iron per pt.wt. of whey protein, and has no iron astringent taste. The concentrate is produced by mixing ferrous ion-containing aqueous solution with whey followed by ultrafiltrating, or mixing ferrous ion with ultrafiltrated whey.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Game Ready shoulder wrap is applied in operating room and used in recovery room for 45 mins to 1 hour. Postop Day 1 and 2: the unit will be applied by the patient or a health care provider; as cold as comfortable (34°F; adjustable to 50°F); low compression setting; 30 min on:60 min off (use the pre-set auto program); use throughout the day; use at night as needed. Postop day 3-14 and onwards: 30 min on:60 min off (use the pre-set auto program); medium compression; as cold as comfortable (34°F; adjustable to 50°F); use minimum of twice/day. This will be combined with pain management medications, range of motion, and positioning exercises.
Chronic HCV patients. Fifteen subjects will receive 1.0 ml of low dose vaccine at weeks 0, 8 and 16 through subcutaneous route.
The disclosure is directed to a beverage sachet including a powder which includes protocatechuic acid, an electrolyte, and a sweetener. The sachet can further include a cannabinoid. The cannabinoid may be cannabidiol. The electrolyte may include sodium chloride salt or monopotassium phosphate salt. The sachet may further include vitamin C, vitamin D, a B vitamin, magnesium, or calcium. The sweetener may include sucrose, glucose, dextrose, maltodextrins, or fructose. The disclosure also includes a beverage including protocatechuic acid and a cannabinoid. The cannabinoid may be cannabidiol. The beverage may be a sports beverage including sweeteners and electrolytes. The beverage may be a health beverage including a fruit, a vegetable, vitamin C, vitamin D, a B vitamin, magnesium, or calcium.
The invention discloses brown sugar for treating dysmenorrhea and a preparation method of the brown sugar, belonging to the field of foods and solving the problem that brown sugar in the prior art has a single component and cannot be used for treating dysmenorrhea. The brown sugar disclosed by the invention comprises 30-100 parts of brown sugar, 10-15 parts of fruit of branchy paliurus, 10-50 parts of cassia twigs, 3-18 parts of abacopteris multilineata (wall.) Ching, 3-30 parts of argyranthemum frutescens, 3-18 parts of galium boreale linn and 3-18 parts of Korean raspberry root. The preparation method comprises the following steps: (1) weighing fruit of branchy paliurus, cassia twigs, abacopteris multilineata (wall.) Ching, argyranthemum frutescens, galium boreale linn and Korean raspberry root, uniformly mixing and crushing all the components, adding water into mixed powder, extracting effective components, and concentrating to obtain a medicine solution; (2) putting brown sugar into the concentrated medicine solution, agitating for dissolving, and homogenizing; and (3) spraying and drying to obtain the brown sugar powder for treating dysmenorrhea. The brown sugar provided by the invention contains traditional Chinese medicines for treating dysmenorrhea and traditional Chinese medicines for treating irregular menstruation; and all the components are reasonably matched so that the brown sugar provided by the invention has the effect of effectively treating dysmenorrhea.